“Hello…hello,” the woman called to me. “Do you work there?” she asked pointing to the Hepatitis SA office. I nodded.
“Can I talk to you, ask you something?” she continued. She needed to get back to the hospital where she worked; her lunch break was almost over, so we spoke as she walked. Shui* told her story and gave me her contact details.
Continue reading “Life, Relationships and Hepatitis B”
By Margaret Randle
& Notes from Meagan Stanfield
This was the first Harm Reduction Conference since 2019 and everyone was excited to hear what Australia had been doing as an early adopter of health-based approaches to drug use. I wanted to hear about what was going on in the Southeast Asian region, as they are our closest neighbours and notoriously hard-line on drug users, with alarming rates of incarceration of women and the use of death penalties for drug offences. Sadly, most of the would-be attendees from Southeast Asia were not given visas.
Continue reading “HR 23: Strength In Solidarity – Part 2”
By Carol Holly
The Harm Reduction conference is held in a different country every two years and provides a forum for sharing the latest research, programs and policy in drug use, harm reduction* and human rights. The conference is convened by Harm Reduction International (HRI) – an organisation that promotes harm reduction and rights-based, evidence-based responses to drug use.
Continue reading “HR 23: Strength In Solidarity – Part 1”
The rate of hepatitis C infections in Aboriginal and Torres Strait Islander communities in Australia is increasing even as infection rate decreases in the wider community. This is despite the introduction of direct-acting antiviral (DAA) drugs that offer the chance to completely eliminate the hepatitis C virus (HCV).
Continue reading “Hep C Treatment Barriers for Rural Aboriginal South Australians”
Going beyond pregnancy and COVID-19, the world could someday soon come to rely on at-home tests for many diseases thanks in part to AI-fuelled improvements. University of Florida (UF) scientists have used artificial intelligence tools to simplify a test that works for both hepatitis C and SARS-CoV-2, the virus that causes COVID-19. The simplified test happens in one small test tube in just a few minutes. With further refinement, it could come to doctor’s offices soon and, one day, even home tests that are as easy as a pregnancy test.
Continue reading “Creating a Hep C Home Test—with AI”
Chronic hepatitis C virus (HCV) infection affects around 3.5 million children worldwide, and in Australia, it’s estimated that it affects at least 4 children per million under 15 years old. Children with chronic hepatitis C infection can suffer from reduced quality of life, social stigmatisation, and inadequate access to specialist care. As with adults, the disease can progress to hepatic fibrosis, chronic liver disease, and hepatocellular cancer.
Continue reading “DAA Treatment for Children”